18. Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.Cruz C(1)(2)(3), Castroviejo-Bermejo M(1), Gutiérrez-Enríquez S(4), Llop-Guevara A(1), Ibrahim YH(1), Gris-Oliver A(1), Bonache S(4), Morancho B(5), Bruna A(6),Rueda OM(6), Lai Z(7), Polanska UM(8), Jones GN(8), Kristel P(9), de Bustos L(1),Guzman M(1), Rodríguez O(1), Grueso J(1), Montalban G(4), Caratú G(10), MancusoF(10), Fasani R(11), Jiménez J(11), Howat WJ(8), Dougherty B(7), Vivancos A(10), Nuciforo P(11), Serres-Créixams X(12), Rubio IT(13), Oaknin A(3)(14), CadoganE(8), Barrett JC(7), Caldas C(15)(16), Baselga J(17)(18), Saura C(3)(19), Cortés J(20)(21), Arribas J(5)(22)(23)(24), Jonkers J(10), Díez O(4)(25), O'ConnorMJ(26), Balmaña J(2)(3), Serra V(1)(24).Author information: (1)Experimental Therapeutics Group.(2)High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona.(3)Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònomade Barcelona, Barcelona.(4)Oncogenetics Group.(5)Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona,Spain.(6)Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University ofCambridge, Cambridge.(7)AstraZeneca, Gatehouse Park, Waltham, USA.(8)DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK.(9)Division of Molecular Pathology and Cancer Genomics, The Netherlands CancerInstitute, Amsterdam, The Netherlands.(10)Cancer Genomics Group.(11)Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona.(12)Department of Radiology.(13)Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron,Universitat Autònoma de Barcelona, Barcelona.(14)Gynecological Malignancies Group, Vall d'Hebron Institute of Oncology,Barcelona, Spain.(15)Department of Oncology and Cancer Research UK Cambridge Institute, Li KaShing Centre, University of Cambridge, Cambridge, UK.(16)Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre andCambridge Experimental Cancer Medicine Centre at Cambridge University HospitalsNHS Foundation Trust, Cambridge, UK.(17)Human Oncology and Pathogenesis Program (HOPP).(18)Department of Medicine, Memorial Sloan Kettering Cancer Center, New York,USA.(19)Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology,Barcelona.(20)Ramón y Cajal University Hospital, Madrid.(21)Vall d'Hebron Institute of Oncology, Barcelona.(22)Department of Biochemistry and Molecular Biology, Building M, Campus UAB,Bellaterra (Cerdanyola del Vallès).(23)Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona.(24)CIBERONC, Barcelona.(25)Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, UniversitatAutònoma de Barcelona, Barcelona, Spain.(26)DNA Damage Response Biology Area, Oncology Innovative Medicine and EarlyDevelopment Biotech Unit, AstraZeneca, Cambridge, UK.Background: BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impairedhomologous recombination repair (HRR) and enhanced sensitivity to DNA damagingagents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Theirefficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers hasbeen recently confirmed in clinical trials. Numerous mechanisms of PARPiresistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity.Patients and methods: We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differentialresponse to PARPi. Analysis included exome sequencing and immunostaining of DNAdamage response proteins to functionally evaluate HRR. Findings were validated ina retrospective sample set from gBRCA1/2-cancer patients treated with PARPi.Results: RAD51 nuclear foci, a surrogate marker of HRR functionality, were theonly common feature in PDX and patient samples with primary or acquired PARPiresistance. Consistently, low RAD51 was associated with objective response toPARPi. Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of themodels, TP53BP1-loss in 20% and RAD51-amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant gBRCA2 tumors displayed BRCA2restoration by exome sequencing. In PDXs, PARPi resistance could be reverted uponcombination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor.Conclusion: Detection of RAD51 foci in gBRCA tumors correlates with PARPiresistance regardless of the underlying mechanism restoring HRR function. This isa promising biomarker to be used in the clinic to better select patients forPARPi therapy. Our study also supports the clinical development of PARPicombinations such as those with ATM inhibitors.DOI: 10.1093/annonc/mdy099 PMCID: PMC5961353PMID: 29635390 